Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

Conditions

• Adult Favorable Prognosis Hodgkin Lymphoma
• Adult Lymphocyte Depletion Hodgkin Lymphoma
• Adult Lymphocyte Predominant Hodgkin Lymphoma
• Adult Mixed Cellularity Hodgkin Lymphoma
• Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
• Adult Nodular Sclerosis Hodgkin Lymphoma
• Adult Unfavorable Prognosis Hodgkin Lymphoma
• Recurrent Adult Hodgkin Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• vorinostat — DRUG
  Given orally
• laboratory biomarker analysis — OTHER
  Correlative studies

Study Details

This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date

Sep 30, 2005

Status verified

Jan 2013

Primary completion

May 31, 2009

Completion

May 31, 2009

Study Design

Enrollment

27 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (vorinostat)
  Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.

Primary Outcome Measure

Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) [ Time Frame: after every 3 cycles on treatment ]

Locations (1)

Find similar trials in San Antonio, TX